| Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical … C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ... JAMA oncology 5 (3), 343-350, 2019 | 411 | 2019 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 309 | 2020 |
| Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer C Cremolini, C Antoniotti, A Stein, J Bendell, T Gruenberger, D Rossini, ... Journal of Clinical Oncology 38 (28), 3314-3324, 2020 | 229 | 2020 |
| Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label … C Antoniotti, D Rossini, F Pietrantonio, A Catteau, L Salvatore, S Lonardi, ... The Lancet Oncology 23 (7), 876-887, 2022 | 174 | 2022 |
| Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic … R Moretto, C Cremolini, D Rossini, F Pietrantonio, F Battaglin, A Mennitto, ... The oncologist 21 (8), 988-994, 2016 | 146 | 2016 |
| Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial E Martinelli, G Martini, V Famiglietti, T Troiani, S Napolitano, ... JAMA oncology 7 (10), 1529-1535, 2021 | 129 | 2021 |
| RET fusions in a small subset of advanced colorectal cancers at risk of being neglected F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, F Morano, G Fucà, ... Annals of Oncology 29 (6), 1394-1401, 2018 | 105 | 2018 |
| Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study C Cremolini, F Morano, R Moretto, R Berenato, E Tamborini, F Perrone, ... Annals of Oncology 28 (12), 3009-3014, 2017 | 98 | 2017 |
| Innovative combination of QuEChERS extraction with on-line solid-phase extract purification and pre-concentration, followed by liquid chromatography-tandem mass spectrometry … D Rossini, L Ciofi, C Ancillotti, L Checchini, MC Bruzzoniti, L Rivoira, ... Analytica chimica acta 935, 269-281, 2016 | 73 | 2016 |
| AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic … C Antoniotti, B Borelli, D Rossini, F Pietrantonio, F Morano, L Salvatore, ... BMC cancer 20, 1-9, 2020 | 68 | 2020 |
| KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population M Schirripa, F Nappo, C Cremolini, L Salvatore, D Rossini, M Bensi, ... Clinical Colorectal Cancer 19 (3), 219-225, 2020 | 65 | 2020 |
| Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer F Loupakis, R Moretto, G Aprile, M Muntoni, C Cremolini, D Iacono, ... British journal of cancer 114 (1), 30-36, 2016 | 64 | 2016 |
| Trifluridine/Tipiracil (TAS‐102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program C Cremolini, D Rossini, E Martinelli, F Pietrantonio, S Lonardi, S Noventa, ... The Oncologist 23 (10), 1178-1187, 2018 | 62 | 2018 |
| FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials C Cremolini, F Loupakis, G Masi, S Lonardi, C Granetto, ML Mancini, ... Annals of Oncology 27 (5), 843-849, 2016 | 61 | 2016 |
| Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS … D Rossini, C Antoniotti, S Lonardi, F Pietrantonio, R Moretto, L Antonuzzo, ... Journal of Clinical Oncology 40 (25), 2878-2888, 2022 | 60 | 2022 |
| Prognostic impact of ATM mutations in patients with metastatic colorectal cancer G Randon, G Fucà, D Rossini, A Raimondi, F Pagani, F Perrone, ... Scientific reports 9 (1), 2858, 2019 | 58 | 2019 |
| Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram F Pietrantonio, R Miceli, L Rimassa, S Lonardi, G Aprile, A Mennitto, ... Annals of Oncology 28 (3), 555-561, 2017 | 54 | 2017 |
| Applicability of the direct injection liquid chromatographic tandem mass spectrometric analytical approach to the sub-ng L− 1 determination of perfluoro-alkyl acids in waste … L Ciofi, L Renai, D Rossini, C Ancillotti, A Falai, D Fibbi, MC Bruzzoniti, ... Talanta 176, 412-421, 2018 | 53 | 2018 |
| Liquid chromatographic/electrospray ionization quadrupole/time of flight tandem mass spectrometric study of polyphenolic composition of different Vaccinium berry … C Ancillotti, L Ciofi, D Rossini, U Chiuminatto, J Stahl-Zeng, S Orlandini, ... Analytical and bioanalytical chemistry 409, 1347-1368, 2017 | 52 | 2017 |
| Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications R Moretto, A Elliott, J Zhang, H Arai, MM Germani, V Conca, J Xiu, ... JNCI: Journal of the National Cancer Institute 114 (2), 271-279, 2022 | 47 | 2022 |
